For people with lung cancer, the hardest part is often that treatments run out. You try one, then another, and each time the cancer finds a way back. Now, a new class of drugs called antibody-drug conjugates (ADCs) is changing that story. Instead of being saved for later, these drugs are being tested as first-line treatments, right from the start.
ADCs work like guided missiles. They attach to specific proteins on cancer cells and deliver a strong chemotherapy payload directly to the tumor. In this review, researchers looked at ADCs targeting proteins like TROP2, HER2, Nectin-4, PD-L1, c-Met, B7-H3, DLL3, and SEZ6 in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). They also explored combining ADCs with immune checkpoint inhibitors, another type of cancer drug.
The big idea is that ADCs could move from later-line treatment, after other drugs fail, to first-line combination regimens. That could mean more options earlier for patients. But there is a catch. Many of these strategies are still in early testing, often reported only at conferences, not yet in peer-reviewed studies. They need confirmation in larger, randomized trials before we know if they truly help people live longer or better.
So while the direction is promising, it is not yet proven. For now, this is a sign of progress, not a guarantee. If you or a loved one are facing lung cancer, talk with your doctor about what is known and what is still experimental.
